Corbett Accel taps Cooper-Broski as new EVP,CMO

Share this article:

Omnicomm unit Corbett Accel Healthcare Group has hired 30-year advertising veteran Elisa Cooper-Broski, to serve as its new EVP and chief marketing officer (CMO).

In her new role, Cooper-Broski will direct Corbett Accel's business development strategy and lead brand-building efforts for the company's five business units in conjunction with the business unit leaders.

Cooper-Broski will be based in Corbett Accel's New York office and will report directly to CEO Scott Cotherman.

“The CMO role is relatively unknown in pharmaceutical advertising,” said Cotherman. "We are one of the first to identify the value a chief marketing officer brings to an organization. Elisa Cooper-Broski's extensive knowledge of the pharmaceutical industry, along with her multi-faceted experience, will be invaluable as we advance our integrated business development strategy."

Cooper-Broski previous experience includes work with GSW New York's presence, Saatchi & Saatchi Healthcare (formerly Klemtner Advertising) CommonHealth USA and NCI Advertising (formerly Rolf Werner Rosenthal).

Prior to joining Corbett Accel, Cooper-Broski was president and chief branding officer for Bruce Leeb & Company, a privately held healthcare advertising agency.

“In this environment, my role as CMO will strengthen the overall impact of Corbett Accel and its business units in the pharmaceutical industry as a communications company that delivers visionary results with substantial and beneficial outcomes” said Cooper-Broski in a statement.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...